Kornimate/medical-research-clean huggingface dataset:
absorption and distribution of glucosamine and chondroitin

Conditions: Osteoarthritis

Summary: the purpose of this study is to examine the way the dietary supplements glucosamine and chondroitin are absorbed and distributed throughout the body.

osteoarthritis is the most common musculoskeletal disease in the world. while predisposing conditions have been identified, the actual cause of osteoarthritis remains unknown. traditional treatments, most often anti-inflammatory drugs and pain relievers, produce variable results and may cause significant toxicity. the use of complementary and alternative therapies in the treatment of osteoarthritis has become more common, and particular interest has focused on glucosamine and chondroitin treatments. this study will examine the pharmacokinetics of glucosamine and chondroitin. this study consists of two phases. in phase i, participants will have two study visits, during which multiple blood samples will be taken to determine levels of glucosamine and chondroitin found naturally in the body. during phase ii, participants will be randomly assigned to receive glucosamine, chondroitin, or a combination of the two for 3 months. blood samples will be taken at each of the three phase ii study visits to examine the pharmacokinetics of glucosamaine and chondroitin.

Eligibility criteria:
inclusion criteria: * able to walk exclusion criteria: * allergy to glucosamine, chondroitin, or shellfish * liver or kidney disease * diabetes mellitus * concurrent use of other complementary or alternative therapies

Keywords: complementary therapies
registry study on epidemiological and biological disease profile as well as clinical outcome in patients with low grade gliomas

Conditions: Glioma

Summary: the log-glio-registry is based on a network of german hospitals gathering radiological, clinical, epidemiological and molecular data on all patients diagnosed with a low grade glioma.


Eligibility criteria:
inclusion criteria: * patients with radiological suspected diagnosis of a low grade glioma * age ≥ 18 years. there is no upper age limit. exclusion criteria: * severe neurological or psychiatric disorder interfering with ability to give an informed consent * no consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician about study participation * no consent for bio-banking of patient's biological specimens and performance of analyses on stored material.

Keywords: low grade glioma, registry, neurosurgery, brain tumor
reusable face masks to reduce risk of viral respiratory infections and asthma exacerbations

Conditions: Acute Respiratory Infection; Asthma Exacerbations

Summary: remask trial is a trial within cohort study (twics), nested within the covidence uk longitudinal study. it has been designed to determine whether the offer of a free reusable, elastomeric face mask to adults with asthma and other members of their household reduces risk of rt-pcr confirmed viral respiratory infections and asthma exacerbations.


Eligibility criteria:
eligibility criteria, participants with asthma ('index participants'): inclusion criteria: * aged 16 or more years * doctor diagnosis of asthma * current prescription for treatment of asthma * participant in covidence uk nasal swab study exclusion criteria: * regularly using any ffp-rated face mask when in an indoor public place * currently sharing household with one or more children * currently sharing household with one or more other covidence uk participants who have asthma * unable to tolerate wearing face mask eligibility criteria, household members of index participants: inclusion criteria * age 16 or more * living in same household as index participant who has consented to take part in trial exclusion criteria - unable to tolerate wearing face mask

Keywords: upper respiratory infection acute respiratory infection asthma exacerbation lower respiratory infection reusable face mask
pgi2 versus nitroglycerine for management of pulmonary hypertension after valve surgeries

Conditions: Pulmonary Hypertension

Summary: this study was conducted in 120 patients aged from 54-65 years scheduled for elective valve replacement surgeries. patients were randomly allocated to nitro glycerine or pgi2 groups. patients of nitro glycerine group received nebulized nitro glycerine at a rate of 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser. patients of pgi2 group received nebulized pgi2 (epoprostenol), 20000 ng/ml (20000 ng/ml in 60 ml syringe was attached to an intravenous pump which delivers a titrating rate of 8 ml/h . the primary outcome was mean pulmonary artery pressure. the secondary outcomes included mean arterial blood pressure (map) (mmhg), pao2/fio2 ratio, cardiac index (ci) (l/min/m2) right ventricular ejection fraction (rvef), central venous pressure(cvp) , 30-day mortality rate and the incidence of complications such as facial flushing, hypotension and re-exploration for bleeding.

postoperative pulmonary hypertension (pht) is the most challenging complication of valvular heart disease about 73% of the patients particularly in those posted for mitral valve replacement surgery methods this prospective study was conducted in 120 patients aged from 54-65 years scheduled for elective valve replacement surgeries. patients were randomly allocated to either nitro glycerine or pgi2 groups. patients of nitro glycerine group received nebulized nitro glycerine (its starting concentration was 200 mcg/ml); nitro glycerine was delivered at a rate of 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit. patients of pgi2 group received nebulized pgi2 (epoprostenol), 20000 ng/ml (20000 ng/ml in 60 ml syringe was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment. the primary outcome was mean pulmonary artery pressure. the secondary outcomes included mean arterial blood pressure (map) (mmhg), pao2/fio2 ratio, cardiac index (ci) (l/min/m2) right ventricular ejection fraction (rvef), central venous pressure(cvp) measured at the end of cardiopulmonary bypass then 30 minutes after start of treatment then 4 hours after start of treatment, 30-day mortality rate and the incidence of complications such as facial flushing, hypotension and re-exploration for bleeding.

Eligibility criteria:
inclusion criteria: * 35 to 66 years old * elective valve replacement surgery * pulmonary arterial hypertension exclusion criteria: * emergency surgery * severe renal and hepatic dysfunction * uncontrolled supraventricular arrhythmia * those requiring preoperative inotropes

Keywords: pgi2 nitroglycerine valve replacement surgery pulmonary hypertension
safety, tolerability, and efficacy of anti-spike (s) sars-cov-2 monoclonal antibodies for the treatment of ambulatory adult and pediatric patients with covid-19

Conditions: COVID-19

Summary: phase 1 * to evaluate the safety and tolerability of regn10933+regn10987 compared to placebo * to evaluate the virologic efficacy of regn10933+regn10987 compared to placebo in reducing viral load of sars-cov-2 phase 2 • to evaluate the virologic efficacy of regn10933+regn10987 compared to placebo in reducing viral load of sars-cov-2 phase 3 * cohort 1 (≥18 years old, not pregnant at randomization) • to evaluate the clinical efficacy of regn10933+regn10987 compared to placebo as measured by covid-19-related hospitalizations or all-cause death * cohort 2 (\<18 years old, not pregnant at randomization) * to evaluate the safety and tolerability of regn10933+regn10987 compared to placebo * to further characterize the concentrations of regn10933 and regn10987 in serum over time * cohort 3 (pregnant at randomization) • to evaluate the safety and tolerability of regn10933+regn10987


Eligibility criteria:
key inclusion criteria: * has sars-cov-2-positive diagnostic test (from a sample collected ≤72 hours prior to randomization, using a validated sars-cov-2 antigen, rt-pcr, or other molecular diagnostic assay, and an appropriate sample such as nasopharyngeal \[np\], nasal, oropharyngeal \[op\], or saliva) * has symptoms consistent with covid-19, as determined by the investigator, with onset ≤7 days before randomization * maintains o2 saturation ≥93% on room air * is able to understand and complete study-related questionnaires (patients aged ≥12 years only) key exclusion criteria: * was admitted to a hospital for covid-19 prior to randomization, or is hospitalized (inpatient) for any reason at randomization * has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), or intravenous immunoglobulin (ivig) within 3 months or within 5 half-lives of the investigational product (whichever is longer) prior to the screening visit * prior, current, or planned future use of any of the following treatments: covid-19 convalescent plasma, mabs against sars-cov-2 (eg, bamlanivimab), ivig (any indication), systemic corticosteroids (any indication), or covid-19 treatments (authorized, approved, or investigational) * prior use (prior to randomization), current use (at randomization) or planned use (within 90 days of study drug administration or per current cdc recommendations, as applicable) of any authorized or approved vaccine for covid-19 * has participated, is participating or plans to participate in a clinical research study evaluation any authorized, approved or investigational vaccine for covid-19 note: other protocol defined inclusion/exclusion criteria apply

Keywords: coronavirus disease 2019 (covid-19) severe acute respiratory syndrome coronavirus 2 (sars-cov-2) coronavirus
nst-spark: preliminary study of an augmented reality (ar) app delivering recovery-oriented cognitive therapy for negative symptoms in schizophrenia

Conditions: Negative Symptoms in Schizophrenia; Schizophrenia; Schizoaffective Disorder

Summary: this study evaluates the feasibility and acceptability of a prototype for nst-spark (version 1.5). this is an augmented reality (ar) mobile phone application that uses recovery-oriented cognitive therapy (ct-r) to target negative symptoms of schizophrenia. nst-spark uses a game ar activity to recapitulate the beginning activation and engagement phase of each ct-r session as per standardized practices for this therapeutic modality.

the specific beliefs targeted during each module are queried before engaging in the ar activity to obtain participant buy in. a self-assessment is taken before and then subsequent prompts challenge these beliefs over the course of the activity. after completion of the ar activity the self-assessment is performed again and the results are compared against the pre-activity responses. the responses received pre- and then post- activity determine the responses spark provides to the participant. example: question: how ambitious or motivated do you feel now? if the post activity response shows a higher level of motivation compared to the pre-activity assessment the participant will receive the following: so you felt more motivated and more energized! and you did more work not less! like the more you do the better you feel. the prototype nst-spark v.1.5 has 2 modules: 1) spark energy and 2) spark motivation, and is an abbreviated experience following the general framework for nst-spark.

Eligibility criteria:
inclusion criteria: * meets dsm-5 criteria for schizophrenia, schizoaffective disorder, schizophreniform disorder, or unspecified psychotic disorder. * presence of negative symptoms - sans rating of 2 or higher on either avolition/apathy or anhedonia/asociality subscale. * capacity to understand the study procedures and provide informed consent. * has dependable access to a device with videoconferencing capability and stable wifi connection which can be accessed by the study iphone. * proficient in english. exclusion criteria: * recent change in level of care: antipsychotic medication changes in the last 4 weeks or hospitalization or emergency room/crisis visits in the last 12 weeks. * acute safety risk - any indication of ongoing risk to themselves or others. * substance induced psychotic disorder or primary mood disorder with psychosis. * severe cognitive or physical limitations preventing the participant from being able to independently use nst-spark.

Keywords: schizophrenia digital therapeutic schizoaffective disorder negative symptoms
psychological impact of the covid-19 pandemic on student nurses

Conditions: Nurse; Student; Post Traumatic Stress Disorder; COVID-19

Summary: the world health organization (who) declared in early 2020 the emergence of a new highly contagious sars-cov-2 coronavirus responsible for a global public health emergency. in france, the first cases of contamination have been reported since the end of january 2020, and the first death in mid-february 2020. then, data published by public healh france reported an increasing and rapidly exponential number of contaminations. first cases have been identified on a cluster mode, then rapidly spreading in some french departments and regions, indicating rapid kinetics of virus spread. given the magnitude of the situation both french territory and neighboring european territories (mainly italy), the government mobilized the entire health system to critically manage this epidemic. this exceptional and unprecedented pandemic deeply impacted the health structures, disrupting healthcare organizations. all caregivers, including all student nurses, actively participated in the mobilization and strengthening of care teams. the health crisis exposed the population of caregivers to potentially traumatic events which can have major repercussions on their health state. the description and identification of the risk factors of the occurrence of post traumatic stress disorders in student nurses during the health crisis would allow to provide avenues for improving training devices and to facilitate health workers access to specific psychological care particularly dedicated to the student nurses population needs.

describe the prevalence of post-traumatic stress disorder among student nurses 1 month after the end of the french epidemic covid-19 peak

Eligibility criteria:
inclusion criteria: * age\>18 years old exclusion criteria: * opposition to participate to the questionnaire

Keywords: student nurses covid-19 post tramatic stress disorder
ps-341 in treating patients with metastatic kidney cancer

Conditions: Kidney Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of ps-341 in treating patients who have metastatic kidney cancer.

objectives: * determine the efficacy of ps-341 in patients with metastatic renal cell carcinoma. * determine the safety of this drug in these patients. outline: this is an open-label study. patients receive ps-341 iv over 3-5 seconds twice weekly for 2 weeks. treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. patients are followed at 2 weeks. projected accrual: a total of 12-37 patients will be accrued for this study within 6-19 months.

Eligibility criteria:
disease characteristics: * histologically confirmed renal cell carcinoma * metastatic disease * unidimensionally measurable disease * no brain metastases patient characteristics: age: * not specified performance status: * karnofsky 70-100% life expectancy: * more than 3 months hematopoietic: * wbc at least 3,000/mm\^3 * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 hepatic: * bilirubin no greater than 1.5 mg/dl * alt/ast no greater than 2.5 times upper limit of normal (uln) renal: * creatinine no greater than 1.5 times uln other: * no pre-existing neuropathy of grade 1 or greater * no other malignancy within the past 5 years, except completely resected basal cell skin cancer, unless treated with potentially curative therapy or at low risk for recurrence * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception during and for 4 months after study prior concurrent therapy: biologic therapy: * at least 4 weeks since prior biologic therapy and recovered * no concurrent biologic therapy chemotherapy: * no prior cytotoxic therapy * no concurrent cytotoxic therapy endocrine therapy: * not specified radiotherapy: * at least 4 weeks since prior radiotherapy * no concurrent radiotherapy surgery: * at least 4 weeks since prior major surgery other: * no other concurrent anticancer therapy

Keywords: stage iv renal cell cancer
comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease

Conditions: Covid 19 Disease

Summary: the investigator will select participants with moderate to severe covid 19 disease admitted in fatima memorial hospital. the investigator will divide them in two groups according to convenience sampling. group 1 will be given dexamethasone 8mg/day and group 2 will be given methylprednisolone 1mg/kg/day iv for 5 days. the investigator will compare the improvement in temperature, oxygen requirement and crp level at day zero and day 5 in both the groups.

the investigators enrolled first 100 participants admitted in covid unit of fatima memorial hospital who fulfilled the inclusion criteria and signed informed consent. baseline oxygen saturation and clinical findings were noted. chest x-ray was done on admission. baseline labs were sent, initial level of crp (c-reactive protein) was noted down. patients with oxygen saturation \ 50 and having infiltrates on chest x-ray at the time of admission were considered having severe covid 19 disease. intravenous methylprednisolone in a dose of 1 mg/kg/day in 2 divided doses or dexamethasone 8 mg/day iv was given to alternate patients for 5 days. after 5 days, the investigator again recorded the oxygen saturation, crp level and repeat chest x-ray findings. patients were given tocilizumab and convalescent plasma as and when indicated. oxygen was given by nasal cannula and face mask. patient was shifted to icu if clinical condition deteriorated and/or mechanical ventilation is needed. the investigator noted the improvement in clinical, radiological and biochemical parameters of the patient on day 0 that is admission day and later on day 5 after giving steroids (methylprednisolone or dexamethasone) for 5 days. data was analyzed using spss version 25.0. descriptive statistics like frequency and means were calculated. paired sample t-test was applied for comparison of the two groups.

Eligibility criteria:
inclusion criteria: 1. age 18 to 75 years 2. covid pcr positive 3. patient having oxygen saturation \< 94% on room air, regardless of chest x-ray findings 4. moderate or severe covid 19 disease according to operational definition. 5. patients who sign informed consent. exclusion criteria: 1. severe immunosuppression like hiv( human immunodeficiency virus) or long term use of immunosuppressant for any other chronic illness 2. patients who need corticosteroids for any other disease like asthma, rheumatoid arthritis. 3. pregnant or lactating females

Keywords: covid19 dexamethasone methlprednisolone corticosteroids
aerobic exercise after traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: the purpose of this study is to examine the effects of individualized aerobic exercise regimen on recovery after traumatic brain injury (tbi).investigators will determine if exercise facilitates recovery by facilitating neuroplasticity and decreasing neuroinflammation.

exercise-based therapies can promote recovery of function and are easily implemented in the clinical rehabilitation setting. this study will determine if exercise facilitates recovery by improving markers of neuroplasticity and decreasing neuroinflammatory responses. the investigators will also determine if variations in genes involved in neuroplasticity, and inflammation influence the responsiveness to exercise and rehabilitation. recovery will be determined by assessing cognitive function, life quality and balance.

Eligibility criteria:
inclusion criteria: * all participants will provide informed consent and have to comply with the procedures of the study. * age will range from 18 to 60 years. * except for the non-injured control group, subjects will be required to have experienced tbi. * all participants should be fluent in english or spanish. * all participants should have the ability to comply with the research protocol. * capable of exercising in aerobic exercise equipment (with or without trunk support). * able to walk independently with or without a device exclusion criteria: * current diagnosis of degenerative neurological disease. * a history of cerebral vascular accidents. * a history of major psychosis as defined by dsm-iv. * subjects receiving physical therapy in a location that is not cns. * pregnancy. * a history of previous tbi requiring hospitalization. * inability to cooperate * orthopedic impairment that compromises exercise performance * any cardiovascular or respiratory condition that jeopardizes patient health during exercise.